Piper Jaffray Companies set a $208.00 target price on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report sent to investors on Wednesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
A number of other research firms have also recently commented on JAZZ. Morgan Stanley cut shares of Jazz Pharmaceuticals from an overweight rating to an equal weight rating and set a $183.00 target price for the company. in a report on Wednesday, July 11th. Stifel Nicolaus increased their target price on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the stock a buy rating in a report on Wednesday, August 8th. Cantor Fitzgerald set a $203.00 target price on shares of Jazz Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, August 7th. Zacks Investment Research cut shares of Jazz Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, July 10th. Finally, Evercore ISI reissued a buy rating on shares of Jazz Pharmaceuticals in a report on Friday, July 13th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $191.94.
Shares of JAZZ stock traded up $3.38 on Wednesday, reaching $145.57. The company had a trading volume of 1,051,546 shares, compared to its average volume of 631,079. The stock has a market capitalization of $8.47 billion, a P/E ratio of 15.23, a price-to-earnings-growth ratio of 0.76 and a beta of 1.06. The company has a current ratio of 4.29, a quick ratio of 3.62 and a debt-to-equity ratio of 0.52. Jazz Pharmaceuticals has a one year low of $130.15 and a one year high of $184.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, topping analysts’ consensus estimates of $3.32 by $0.26. The firm had revenue of $469.37 million during the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.22 earnings per share. As a group, equities analysts predict that Jazz Pharmaceuticals will post 11.71 EPS for the current fiscal year.
In related news, CEO Bruce C. Cozadd sold 1,300 shares of the firm’s stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $164.36, for a total value of $213,668.00. Following the completion of the transaction, the chief executive officer now owns 281,215 shares in the company, valued at approximately $46,220,497.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $158.08, for a total transaction of $110,656.00. Following the completion of the transaction, the chief financial officer now owns 32,768 shares of the company’s stock, valued at approximately $5,179,965.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,730 shares of company stock valued at $2,796,532. 3.90% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Stratos Wealth Partners LTD. bought a new position in Jazz Pharmaceuticals in the 3rd quarter valued at approximately $106,000. Tiverton Asset Management LLC bought a new position in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $198,000. Moloney Securities Asset Management LLC bought a new position in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $204,000. FDx Advisors Inc. acquired a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $244,000. Finally, Cadence Capital Management LLC acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $263,000. Institutional investors and hedge funds own 92.95% of the company’s stock.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: How can investors find ex-dividend dates?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.